Q#5 Best Overall Response (BOR) , Objective Response Rate (ORR) ,95% Confidence Interval (CI) &P-value Oncology

Definition of Best Overall Response (BOR)

Best Overall Response (BOR) is the best treatment response a patient achieves during a clinical trial.

It is determined based on tumor size changes and classified into four categories:

1.Complete Response (CR) – The tumor disappears completely.

2.Partial Response (PR) – The tumor shrinks significantly but is still present.

3.Stable Disease (SD) – The tumor neither shrinks nor grows significantly.

4.Progressive Disease (PD) – The tumor grows or worsens.

Imagine 5 patients are taking a new cancer drug.

Each patient’s response is tracked over time.

•If a patient improves over time, the best response is counted (e.g., PR → CR → CR is recorded as CR).

•If a patient worsens after improvement, the worst response is counted if the patient does not recover

•(e.g., PR → PD is recorded as PD).

Imagine 5 patients are taking a new cancer drug.

Each patient’s response is tracked over time.

•If a patient improves over time, the best response is counted (e.g., PR → CR → CR is recorded as CR).

•If a patient worsens after improvement, the worst response is counted if the patient does not recover

•(e.g., PR → PD is recorded as PD).

PatientResponse TypeBest Overall Response (BOR)
Patient 1CR (Tumor disappeared)CR
Patient 2PR (Tumor shrank)PR
Patient 3SD (No significant change)SD
Patient 4PR first, then PD laterPD (worst response counts)
Patient 5PR first, then CR laterCR (best response counts)

PR → CR → CR → CR

👉 BOR = CR (Best was 100%)SD → PR → PR → SD

👉 BOR = PR (Best was 80%)PR → SD → PD → PD

👉 BOR = PD (Got worse at the end)SD → SD → SD → SD

👉 BOR = SD (No change)PR → CR → PD

👉 BOR = PD (Got worse at the end)Definition of Objective Response Rate (ORR)

Objective Response Rate (ORR) is a measure used in oncology clinical trials to assess how well a treatment works.

It is the percentage of patients whose cancer shrinks (Partial Response – PR) or disappears (Complete Response – CR) after treatment.

ORR does not include Stable Disease (SD) or Progressive Disease (PD).

A 95% Confidence Interval (CI) is a range of values that tells us where the true result is likely to be.

What is a 95% Confidence Interval (CI)?

95% Confidence Interval (CI) for Objective Response Rate

Drug A: (0.1941 – 0.993) → This means we are 95% sure that the true response rate for Drug A is between 19.41% and 99.3%.

Drug B: (0.0250 – 1.000) → The response rate for Drug B is between 2.5% and 100% (very wide range due to low patient count).95% Confidence Interval (CI) for Objective Response Rate

Drug A: (0.1941 – 0.993) → This means we are 95% sure that the true response rate for Drug A is between 19.41% and 99.3%.

Drug B: (0.0250 – 1.000) → The response rate for Drug B is between 2.5% and 100% (very wide range due to low patient count).Difference in Objective Response Rate

0.75 (75%) → Drug A had a 75% higher response rate than Drug B.95% CI for the Difference in ORR

0.3257 → This means the actual difference could vary, but there’s a 32.57% chance that Drug A is better than Drug B.P-value

0.2207 → The p-value tells us if the difference between Drug A and Drug B is statistically significant.

•Since 0.2207 > 0.05, this means the difference is not statistically significant, meaning we cannot be sure that Drug A is truly better than Drug B (the result could be due to chance).

sascodingexpert@gmail.com

20+ clinical SAS Experience

Recent Posts

SAS Tip: Repeating AEBODSYS on New Page in PROC REPORT Output

ADAEDownload ADSLDownload HTML LIBNAME AD "G:\TA_ONCO_01_24122024\ADaM"; /*Macro for sorting purpose*/ %MACRO SORT(in= ,out= ,datacon= ,outcon=…

3 months ago

All Logs checking macro

HTML /* retrieve all the logs in the specified directory */ %macro checklogs(loc=, /* location…

3 months ago

Adverse Event ADaM [ADAE] programming SAS

AEDownload ADSLDownload FINAL ADAM ADAE SPECDownload HTML /******************************************************************* * Client: PHARMA Private Limited. * Project:…

3 months ago

Q#4 Please tell recent 5 studies titles, primary and secondary objectives and End points

1. Study Title: A Randomized Phase 3 Study of MRTX949 versus Docetaxel in Patients with…

4 months ago

SDTM SE (Subject Element ) Dataset Programming

Raw.svDownload SDTM_US.DMDownload SDTMIG_v3.3_FINALDownload HTML ******************************************************************* * Client: PHARMA Private Limited. * Project: Protocol: 043-1-2025 *…

4 months ago

Q#3 Please tell recent 5 studies titles, primary and secondary objectives.

1. A Randomized Phase 3 Study of MRTX949 versus Docetaxel in Patients with Previously Treated…

4 months ago